Jeffrey W. Clark, MD
The Tucker Gosnell Center for Gastrointestinal Cancers
Dr. Clark is a graduate of Massachusetts Institute of Technology, where he graduated Baccalaureate of Science in Biology. He went on to receive his medical degree at Tufts University School of Medicine. His current research efforts involve development of new therapeutic approaches for malignancies and especially for gastrointestinal cancers. Dr. Clark specifically interested in development of approaches targeting proteins mutated or over-expressed in malignant cells, such as Ras and growth factor receptors (e.g. EGFR, HER2). This includes early evaluation of novel agents in phase I studies as well as the integration of these agents with standard chemotherapeutic regimens. For example, he was the principle investigator of an early phase I trial of sorafenib (subsequently approved for hepatocellular and renal cancers) and have been the Dana Farber Harvard Cancer Center (DFHCC) principle investigator of a phase I trial of crizotinib, a small molecule inhibitor of the ALK kinase which has shown significant activity against tumors harboring ALK translocations, including Non-small cell lung cancers that have EML4-ALK translocations.
The other major aspect of Dr. Clark’s clinical research efforts involves evaluation of and efforts to improve the performance of clinical trials in oncology. In addition to continuous reassessment of systems issues in performance of trials, this also involves evaluation of the informed consent process and ways in which this might be improved to be most useful for individuals participating in clinical trials. As part of these responsibilities, he is in charge of the performance of the clinical trial infrastructure of the DFHCC.
Dr. Clark has also been interested in utilization of combined modality (surgery, radiation therapy, and chemotherapy) approaches in treating gastrointestinal malignancies and has worked closely with radiation therapists and surgeons in designing and performing clinical trials evaluating new approaches aimed at enhancing therapeutic efficacy in this setting. From 1995-2004, he helped expand the GI Medical Oncology program at MGH from one full-time individual to a program that now has six full-time physicians. This included recruiting these physicians as well as mentoring the current leader of GI Medical Oncology at MGH, Dr. Ryan.